Glycyrrhizin has demonstrated therapeutic potential for psoriasis by alleviating adverse symptoms in an IMQ-induced mouse model, improving the pathological state of skin cells, and inhibiting IL-17A and IFN-γ expression. This evidence concerns the gene IFNG and psoriasis.